

World Journal of *Gastrointestinal Pathophysiology*

World J Gastrointest Pathophysiol 2012 August 15; 3(4): 85-91





Editorial Board

2010-2015

The *World Journal of Gastrointestinal Pathophysiology* Editorial Board consists of 296 members, representing a team of worldwide experts in gastrointestinal pathophysiology. They are from 39 countries, including Argentina (1), Australia (5), Austria (1), Belgium (6), Brazil (7), Brunei Darussalam (1), Canada (15), China (18), Croatia (1), Czech Republic (2), Denmark (2), Egypt (1), Estonia (1), France (5), Germany (17), Greece (2), Hungary (2), India (7), Iran (1), Ireland (1), Israel (3), Italy (23), Japan (21), Lebanon (1), Malaysia (1), México (2), Netherlands (3), Norway (1), Poland (3), Russia (1), Singapore (3), South Korea (7), Spain (12), Sweden (6), Switzerland (2), Turkey (2), Ukraine (1), United Kingdom (7), and United States (101).

EDITOR-IN-CHIEF

Thomas Y Ma, *Albuquerque*

STRATEGY ASSOCIATE

EDITORS-IN-CHIEF

Jean François Beaulieu, *Quebec*
Hirotada Akiho, *Fukuoka*
Sharon DeMorrow, *Texas*

GUEST EDITORIAL BOARD

MEMBERS

Chien-Wei Hsu, *Kaohsiung City*
Jin-Town Wang, *Taipei*

MEMBERS OF THE EDITORIAL BOARD



Argentina

Marcelo G Roma, *Rosario*



Australia

Chris R Abbiss, *Western Australia*
Chandana B Herath, *Victoria*
Quoc N Nguyen, *South Australia*
Nicholas J Spencer, *South Australia*
Shu-Feng Zhou, *Victoria*



Austria

Michael Trauner, *Graz*



Belgium

Robaey Geert, *Genk*
Ilse Maria Hoffman, *Leuven*
Michael HJ Maes, *Wilrijk*
Theodoor A Niewold, *Heverlee*
Jean-Marie Vanderwinden, *Brussels*
Mathieu Vinken, *Roeselare*



Brazil

Uilian Andreis, *Botucatu*
João B Calixto, *Florianópolis*
Niels OS Câmara, *São Paulo*
Fernando Fornari, *Postal Code*
Clélia A Hiruma-Lima, *São Paulo*
Juarez Quaresma, *Belem*
Wagner Vilegas, *San Paolo*



Brunei Darussalam

Vui Heng Chong, *Bandar Seri Begawan*



Canada

Fernando Alvarez, *Quebec*
Francois Boudreau, *Quebec*
George A Bubenik, *Ontario*
Wang-Xue Chen, *Ottawa*
Jan Dirk Huizinga, *Hamilton*
Wolfgang Kunze, *Ontario*
Jian-Jun Li, *Ontario*
Roderick J MacLeod, *Kingston*

Nathalie Rivard, *Quebec*
Kirill Rosen, *Halifax*
Jean Sévigny, *Quebec*
Manuela Santos, *Quebec*
Eldon A Shaffer, *Alberta*
Pierre H Vachon, *Québec*



China

Kai-Xing Ai, *Shanghai*
CH Cho, *Hong Kong*
Zhong-Hong Gao, *Wuhan*
Jing-Yan Han, *Beijing*
Jian-Dong Huang, *Hong Kong*
Xiao-Hong Wang, *Beijing*
Wei Wei, *Hefei*
Dong-Ping Xie, *Shanghai*
Wen-Xie Xu, *Shanghai*
Hua Yang, *Chongqing*
Xiao Yang, *Beijing*
Hua-Chuan Zheng, *Shenyang*
Jin-Xia Zhu, *Beijing*
Min-Sheng Zhu, *Nanjing*
Yong-Liang Zhu, *Hangzhou*



Croatia

Alen Protic, *Rijeka*



Czech Republic

Pavel Hladik, *Semily*
Martin Vokurka, *Praha*

**Denmark**

Lars Arendt Nielsen, *Aalborg*
Jingbo Zhao, *Aalborg*

**Egypt**

Ram I Mahato, *Memphis*

**Estonia**

Enn Seppet, *Tartu*

**France**

Bruno Bonaz, *Grenoble Cedex*
Pierre M Dechelotte, *Rouen*
Jean-Paul Lallès, *Saint Gilles*
Pascale Plaisancié, *Lyon*
Micheline Plateroti, *Lyon*

**Germany**

Carsten Bergmann, *Ingelheim*
Elke Cario, *Essen*
Nikolaus Gassler, *Aachen*
Werner Hartwig, *Heidelberg*
Marion Hewicker-Trautwein, *Hannover*
Tobias Keck, *Freiburg im Breisgau*
Peter Malfertheiner, *Magdeburg*
Christoph Michalski, *Munich*
Andreas Klaus Nüssler, *Munich*
Christian Pehl, *Vilsbiburg*
Peter Schemmer, *Heidelberg*
Marc P Stemmler, *Freiburg*
Frank Tacke, *Aachen*
Sya Nomna Ukena, *Hannover*
Brigitte Vollmar, *Rostock*
Thomas Michael Wex, *Magdeburg*
Margot Zöller, *Heidelberg*

**Greece**

Stelios F Assimakopoulos, *Patras*
George V Papatheodoridis, *Athens*

**Hungary**

Mária Bagyánszki, *Szeged*
Mihály Boros, *Szeged*

**India**

Anil Kumar Agarwal, *Delhi*
Uday Bandyopadhyay, *Kolkata*
Chandra Kanti Chakraborti, *Orissa*
Nilesh M Dagia, *Maharashtra*

Rajeev Garg, *Punjab*
Chandra P Sharma, *Karnataka*
Prabhakar R Veerareddy, *Andhra Pradesh*

**Iran**

Shahram Shahabi, *Urmia*

**Ireland**

Stephen J Keely, *Dublin*

**Israel**

Yosefa Avraham, *Jerusalem*
Yaakov M Kendler, *Tel-Hashomer*
Nachum Vaisman, *Tel Aviv*

**Italy**

Rosaria Acquaviva, *Catania*
Alessandro Antonelli, *Pisa*
Salvatore Auricchio, *Naples*
Claudio Bassi, *Verona*
Massimo Bellini, *Cisanello-Pisa*
Alfio Brogna, *Catania*
Giuseppe Calamita, *Bari*
Ignazio Castagliuolo, *Padova*
Enrico S Corazziari, *Roma*
Francesco Cresi, *Torino*
Rosario Cuomo, *Napoli*
Mario Milco D'Elis, *Florence*
Walter Fries, *Messina*
Marco Gobbetti, *Bari*
Basilisco Guido, *Milano*
Enzo Ierardi, *Foggia*
Pietro Invernizzi, *Rozzano*
Anna Kohn, *Rome*
F. Marotta, *Milano*
Cristiano Rumio, *Milan*
Edoardo Vincenzo Savarino, *Genoa*
Annamaria Staiano, *Naples*
Claudio Tiribelli, *Trieste*

**Japan**

Akihiro Asakawa, *Kagoshima*
Hisashi Aso, *Aoba-ku Sendai*
Hideki Iijima, *Osaka*
Hajime Isomoto, *Nagasaki*
Haruki Kitazawa, *Sendai*
Xiao Kang Li, *Tokyo*
Kazuyuki Matsushita, *Chuo-ku*
Reiko Miyazawa, *Gunma*
Yuji Naito, *Kyoto*
Atsushi Nakajima, *Kanagawa*
Tutomu Nishida, *Osaka*
Koji Nomoto, *Tokyo*
Shouji Shimoyama, *Tokyo*
Ikuo Shoji, *Hyogo*
Hidekazu Suzuki, *Tokyo*

Toru Takahashi, *Okayama*
Yoshihisa Takahashi, *Tokyo*
Takato Ueno, *Kurume*
Yoshiyuki Ueno, *Sendai*
Hitoshi Yoshiji, *Nara*

**Lebanon**

Costantine Fouad Daher, *Byblos*

**Malaysia**

Andrew CS Boon, *Perak*

**Mexico**

José M De la Roca-Chiapas, *Gto*
MR Huerta-Franco, *Guanajuato*

**Netherlands**

Aldo Grefhorst, *Groningen*
Pieter Job Tanis, *Amsterdam*
Cornelis FM Sier, *Leiden*

**Norway**

Anne Marie Bakke, *Oslo*

**Poland**

Stanisław Jan Konturek, *Kraków*
Agata Mulak, *Wrocław*
Napoleon Waszkiewicz, *Choroszcz*

**Russia**

Ludmila Filaretova, *Petersburg*

**Singapore**

Madhav Bhatia, *Singapore*
Brian KP Goh, *Singapore*
Cliff KS Ong, *Singapore*

**South Korea**

Ho Jae Han, *Gwangju*
Ki-Baik Hahm, *Incheon*
Myung Haing Cho, *Seoul*
Chang-Duk Jun, *Gwangju*
Sang Geon Kim, *Seoul*
Won-Jae Lee, *Seoul*
Kwan Kyu Park, *Daegu*



Spain

Raquel Abalo, *Alcorcón*
 Marçal P Anglada, *Barcelona*
 Fernando Azpiroz, *Barcelona*
 Ramón Bataller, *Barcelona*
 Dario A Castroviejo, *Granada*
 Joan Clària, *Barcelona*
 Maria T Martin, *Barcelona*
 Vicente Martinez, *Barcelona*
 Jose M Matés, *Málaga*
 María Eugenia Sáez, *Seville*
 Yolanda Sanz, *Valencia*
 Maria D Yago, *Granada*



Sweden

Frida Fåk, *Göteborg*
 Gunnar FA Flemström, *Uppsala*
 Bob Roger Olsson, *Göteborg*
 Peter Thelin Schmidt, *Stockholm*
 Xiao-Feng Sun, *Linköping*
 Henrik Thorlacius, *Malmö*



Switzerland

Jyrki J Eloranta, *Zurich*
 Catherine Pastor, *Geneva*



Turkey

Mehmet Bektas, *Ankara*
 Muammer Karadeniz, *Manisa*



Ukraine

Oksana S Zayavhivska, *Lviv*



United Kingdom

Fabian Michel Angeli, *Cambridge*
 Geoffrey Burnstock, *London*
 Janice Elizabeth Drew, *Scotland*
 Girish Gupte, *Birmingham*
 Jamie Murphy, *London*

Vadim Sumbayev, *Kent*
 Andrea Varro, *Liverpool*



United States

Gianfranco D Alpini, *Temple*
 Shrikant Anant, *Oklahoma City*
 Gyorgy Baffy, *Massachusetts*
 Michael T Bailey, *Columbus*
 Kim Elaine Barrett, *San Diego*
 Marc D Basson, *Lansing*
 David H Berger, *Texas*
 Qiang Cai, *Atlanta*
 Wei-Biao Cao, *Rhode Island*
 Subhash C Chauhan, *Sioux Falls*
 Jiande Chen, *Texas*
 Tao-Sheng Chen, *Memphis*
 Mashkoor A Choudhry, *Illinois*
 Parimal Chowdhury, *Arkansas*
 Robert Thomas Cormier, *Duluth*
 Srinivasan Dasarathy, *Cleveland*
 Edwin A Deitch, *New Jersey*
 Dan Alan Dixon, *Columbia*
 H Henry Dong, *Pittsburgh*
 Hui Dong, *Carolina*
 Ashkan Farhadi, *Irvine*
 Jenifer I Fenton, *East Lansing*
 Alessandro Fichera, *Chicago*
 Mitchell P Fink, *Pennsylvania*
 Robert Armour Forse, *Omaha*
 Stroud Glaser, *Texas*
 Gondim F de AA Gondim, *Louis*
 Yan-Fang Guan, *Ohio*
 Hartmut Jaeschke, *Kansas*
 Robert Thomas Jensen, *Los Angeles*
 Chris Kevil, *Los Angeles*
 Pawel R Kiela, *Arizona*
 Tammy Lyn Kindel, *Ohio*
 Gordana Kosutic, *Durham*
 Ashok Kumar, *Detroit*
 Muriel Larauche, *Los Angeles*
 Felix W Leung, *North Hills*
 Suthat Liangpunsakul, *Indiana*
 Feng-Xin Lu, *Massachusetts*
 Guang-Xiang Luo, *Lexington*
 Akhil Maheshwari, *Birmingham*
 Kenneth Maiese, *New York*
 Adhip PN Majumdar, *Michigan*
 José E Manautou, *Connecticut*
 Craig J McClain, *Kentucky*
 Beverley GV Meerveld, *Oklahoma City*
 Douglas S Merrell, *Bethesda*

Murielle Mimeault, *Omaha*
 Emiko Mizoguchi, *Boston*
 Adam Moeser, *North Carolina*
 Roger Klein Moreira, *New York*
 Shuji Ogino, *Boston*
 Mary Francis Otterson, *Wisconsin*
 Chung Owyang, *Michigan*
 Helieh S Oz, *Lexingtons*
 Nicholas C Popescu, *Bethesda*
 Chao Qin, *Oklahoma*
 P Rafiee, *Wisconsin*
 Sigrid A Rajasekaran, *Wilmington*
 Ramesh M Ray, *Tennessee*
 Yehuda Ringel, *Chapel Hill*
 Richard A Rippe, *Maryland*
 Chantal A Rivera, *Los Angeles*
 Paul A Rufo, *Boston*
 Sanjaya K Satapathy, *New Hyde Park*
 Anthony Senagore, *Los Angeles*
 Muhammad Y Sheikh, *Fresno*
 Le Shen, *Illinois*
 Frank A Simmen, *Little Rock*
 Steven Mitchell Singer, *Washington*
 Shailinder Jit Singh, *Washington*
 Nicholas James Skill, *Indianapolis*
 Adam Jan Smolka, *Charleston*
 Ned Snyder, *Texas*
 Rhonda Frances Souza, *Dallas*
 Stuart Jon Spechler, *Texas*
 Catia Sternini, *California*
 Yvette Taché, *California*
 Xiao-Di Tan, *Chicago*
 Paul Daniel Terry, *Atlanta*
 Jennifer S Tirnauer, *Farmington*
 George C Tsokos, *Massachusetts*
 Vic Velanovich, *Detroit*
 Estela Wajcberg, *Cranford*
 Arnold Wald, *Madison*
 Li-Xin Wang, *Los Angeles*
 Christian Weber, *Boston*
 Jackie D Wood, *Columbus*
 Guo-Yao Wu, *Texas*
 Christian Wunder, *Bethesda*
 Zuo-Liang Xiao, *Cleveland*
 Guo-Rong Xu, *New Jersey*
 Jay A Yelon, *Valhalla*
 Chiang John YL, *Ohio*
 Shao-Yong Yu, *Pennsylvania*
 Yana Zavros, *Ohio*
 Joerg Zehetner, *Los Angeles*
 Jian X Zhang, *North Carolina*
 Zhi Zhong, *Charleston*
 Qing Zhu, *Maryland*



ORIGINAL ARTICLE

85

Endothelin and neonatal capsaicin regulate gastric resistance to injury in BDL rats

Câmara PRS, Ferraz GJN, Velloso LA, Zeitune JMR, Suassuna FAB, Ferraz JGP

Contents

World Journal of Gastrointestinal Pathophysiology
Volume 3 Number 4 August 15, 2012

ACKNOWLEDGMENTS I Acknowledgments to reviewers of *World Journal of Gastrointestinal Pathophysiology*

APPENDIX I Meetings
I-V Instructions to authors

ABOUT COVER *World Journal of Gastrointestinal Pathophysiology* Editor-in-Chief, Thomas Y Ma, MD, PhD, Professor, Chief, Division of Gastroenterology and Hepatology, University of New Mexico, MSC10 5550, 1 UNM, Albuquerque, NM 87131, United States

AIM AND SCOPE *World Journal of Gastrointestinal Pathophysiology* (*World J Gastrointest Pathophysiol*, *WJGP*, online ISSN 2150-5330, DOI: 10.4291), is a bimonthly, open-access, peer-reviewed journal supported by an editorial board of 296 experts in gastrointestinal pathophysiology from 39 countries.

The major task of *WJGP* is to report rapidly the most recent results in basic and clinical research on gastrointestinal pathophysiology, including all aspects of normal or abnormal function of the gastrointestinal tract, hepatobiliary system, and pancreas. *WJGP* specifically covers growth and development, digestion, secretion, absorption, metabolism and motility relative to the gastrointestinal organs, as well as immune and inflammatory processes, and neural, endocrine and circulatory control mechanisms that affect these organs. This journal will also report new methods and techniques in gastrointestinal pathophysiological research.

FLYLEAF I-III Editorial Board

EDITORS FOR THIS ISSUE

Responsible Assistant Editor: Yuan Zhou
Responsible Electronic Editor: Xiao-Mei Zheng
Proofing Editor-in-Chief: Lian-Sheng Ma

Responsible Science Editor: Jin-Lei Wang
Proofing Editorial Office Director: Jin-Lei Wang

NAME OF JOURNAL
World Journal of Gastrointestinal Pathophysiology

ISSN
ISSN 2150-5330 (online)

LAUNCH DATE
April 15, 2010

Frequency
Bimonthly

EDITING
Editorial Board of *World Journal of Gastrointestinal Pathophysiology*
Room 903, Building D, Ocean International Center,
No. 62 Dongsihuan Zhonglu, Chaoyang District,
Beijing 100025, China
Telephone: +86-10-85381892
Fax: +86-10-85381893
E-mail: wjgp@wjgnet.com
<http://www.wjgnet.com>

EDITOR-IN-CHIEF
Thomas Y Ma, MD, PhD, Professor, Chief, Divi-

sion of Gastroenterology and Hepatology, University of New Mexico, MSC10 5550, 1 UNM, Albuquerque, NM 87131, United States

EDITORIAL OFFICE
Jian-Xia Cheng, Director
Jin-Lei Wang, Vice Director
World Journal of Gastrointestinal Pathophysiology
Room 903, Building D, Ocean International Center,
No. 62 Dongsihuan Zhonglu, Chaoyang District,
Beijing 100025, China
Telephone: +86-10-85381892
Fax: +86-10-85381893
E-mail: wjgp@wjgnet.com
<http://www.wjgnet.com>

PUBLISHER
Baishideng Publishing Group Co., Limited
Room 1701, 17/F, Henan Building,
No.90 Jaffe Road, Wanchai,
Hong Kong, China
Fax: +852-31158812
Telephone: +852-58042046
E-mail: bpgoffice@wjgnet.com
<http://www.wjgnet.com>

PUBLICATION DATE
August 15, 2012

COPYRIGHT
© 2012 Baishideng. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT
All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

INSTRUCTIONS TO AUTHORS
Full instructions are available online at http://www.wjgnet.com/2150-5330/g_info_20100316080008.htm

ONLINE SUBMISSION
<http://www.wjgnet.com/esps/>

Endothelin and neonatal capsaicin regulate gastric resistance to injury in BDL rats

Paula RS Câmara, Gerson JN Ferraz, Licio A Velloso, José Murilo R Zeitune, Fernando AB Suassuna, Jose Geraldo P Ferraz

Paula RS Câmara, Fernando AB Suassuna, Department of Medicine, Potiguar University, RN 59056-000, Brazil
Paula RS Câmara, Gerson JN Ferraz, Licio A Velloso, José Murilo R Zeitune, Jose Geraldo P Ferraz, GI Research Lab, Gastrocentro, Department of Medicine, Faculty of Medical Sciences, University of Campinas, SP 13083-878, Brazil

Jose Geraldo P Ferraz, Division of Gastroenterology, Faculty of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada

Author contributions: Câmara PRS, Ferraz JGP, Velloso LA and Zeitune JMR designed the research; Câmara PRS and Ferraz GJN performed the research; Câmara PRS, Suassuna FAB, Ferraz GJN and Zeitune JMR analyzed the data; Câmara PRS and Ferraz GJN wrote the paper; Zeitune JMR reviewed it. Supported by A fellowship from Fundação de Amparo a Pesquisa do Estado de São Paulo, FAPESP, Brazil (to Câmara PRS) and a research grant from FAPESP (to Ferraz JGP)

Correspondence to: Paula RS Câmara, PhD, Department of Medicine, Potiguar University, Av. Senador Salgado Filho, 1610, 59056-000 - Natal, RN, Brazil. paula.camara@unp.br

Telephone: +55-84-32151273 Fax: +55-84-32151200

Received: January 14, 2012 Revised: August 6, 2012

Accepted: August 10, 2012

Published online: August 15, 2012

Gastric blood flow was measured by laser-Doppler flowmetry.

RESULTS: ET-3 and an ET_B receptor antagonist significantly reduced the extent of ethanol-induced gastric damage in BDL rats. Gastric ET-1 and -3 levels were 30% higher in BDL rats compared to control rats. Capsaicin treatment restored the gastric resistance and blood flow responses to topical application of ethanol in BDL rats and ET-1 and -3 production to levels observed in controls.

CONCLUSION: Our results suggest that the reduced resistance of the gastric mucosa of cirrhotic rats to ethanol-induced injury is a phenomenon modulated by ET through the ET_B receptor and by sensory afferent neurons.

© 2012 Baishideng. All rights reserved.

Key words: Endothelins; Tachykinins; Portal hypertension; Gastropathy; Cirrhosis

Peer reviewer: Liya Qiao, PhD, Assistant Professor, Department of Physiology and Biophysics, School of Medicine, Virginia Commonwealth University, Richmond, VA 23298, United States

Câmara PRS, Ferraz GJN, Velloso LA, Zeitune JMR, Suassuna FAB, Ferraz JGP. Endothelin and neonatal capsaicin regulate gastric resistance to injury in BDL rats. *World J Gastrointest Pathophysiol* 2012; 3(4): 85-91 Available from: URL: <http://www.wjgnet.com/2150-5330/full/v3/i4/85.htm> DOI: <http://dx.doi.org/10.4291/wjgp.v3.i4.85>

Abstract

AIM: To investigate the relationship between primary afferent neurons, endothelin (ET) and the role of its receptors on ethanol-induced gastric damage in cirrhotic rats.

METHODS: Cirrhosis and portal hypertension were induced in rats by bile duct ligation (BDL) while controls had a sham operation. The association between ET and afferent neurons on the gastric mucosa was evaluated by capsaicin treatment in newborn rats, the use of ET agonists or antagonists, gastric ET-1 and -3 mRNA and synthetic capacity. Ethanol-induced damage was assessed using *ex vivo* gastric chamber experiments.

INTRODUCTION

Endothelin (ET) is a family of three distinct peptides (ET-1, -2 and -3), best known for its vascular effects.

However, it also plays a role in modulating pain, independent from its vascular actions. Data suggest that ET is also a neurotransmitter/neuromodulator and can have a direct nociceptive effect on the peripheral sensory nervous system^[1,2].

Pharmacological studies have suggested that ET released in peripheral tissues could act directly on ET_A (ET_A) receptor-expressing sensory neurons and on ET_B (ET_B) receptor-expressing satellite cells in dorsal root ganglia or even in nonmyelinating Schwann cells. ET_A receptor may play a role in signaling acute or neuropathic pain in peripheral tissues, whereas the ET_B receptor may be involved in the transmission of chronic inflammatory pain^[3,4]. ET is a strong stimulus for neuropeptide release in neurogenic inflammation, such as substance P, CGRP and catecholamines^[5-8], as reported in inflammation of the meninges of rats acting through the ET_B receptor^[9]. Moreover, ET-1 potentiation of cholinergic nerve-mediated contraction suggests that, in addition to nerves, the vascular territory and inflammatory cells^[10], other cell types, such as airway smooth muscle cells and human dermal microvascular endothelial cells, can be targeted^[11,12]. Furthermore, ET-1, with the ET_A and ET_B receptors, has been reported to be present in the rat gastrointestinal tract^[13,14] and may be a potent peptide agonist in the liver^[15]. Activation of sensory afferent neurons by a luminal irritant plays a major role in regulating the gastric hyperemic response to irritants with consequent impact on resistance to injury^[16,17].

The objective of this study was to investigate the relationship between ET and sensory primary afferent neurons in the gastric resistance to ethanol-induced injury in cirrhotic rats, integrating the neurogenic component of regulation of gastric mucosal blood flow and gastric resistance to injury by a topical irritant.

MATERIALS AND METHODS

Animals

Male Sprague-Dawley rats (200-250 g) provided by the Animal House of the State University of Campinas (UNICAMP) were used in all experiments. They were housed in plastic cages and had free access to water and standard pellet chow. The experimental protocols were approved by the Ethical Principles in Animal Research adopted by the Brazilian College for Animal Experimentation.

Induction of cirrhosis and portal hypertension by bile duct ligation

Rats were anesthetized using halothane and a midline laparotomy was performed as described previously^[18]. Briefly, bile duct ligation (BDL) was performed by isolating the common bile duct and placing two 4-0 sutures proximal/distal to the porta hepatis. Next, a 5-10 mm segment between ligatures was resected. The abdomen was then sutured with 4-0 silk and the animals were al-

lowed to recover. A separate set of animals, referred to as controls, had a sham operation defined as a laparotomy with isolation, but not resection, of the common bile duct, followed by closure of the abdominal wall. Experiments were performed 4 wk following surgery when liver cirrhosis and portal hypertension were established in BDL but not control rats. The 4 wk time point was chosen, given that in our hands, the animals have clear liver cirrhosis and portal hypertension and also based on previous reports that characterized the structural and hemodynamic changes in this particular experimental protocol^[16-20].

Measurement of mean arterial blood pressure and portal pressure

Mean arterial pressure (mmHg) in conscious control ($n = 5$) or BDL ($n = 5$) rats was measured using a rat tail blood pressure monitor (Harvard Apparatus, Holliston, MS). Portal pressure (mmHg) was measured in rats anesthetized with sodium pentobarbitone (25 mg/kg, ip) by cannulation of the superior mesenteric vein with a PE-20 tube connected to a pressure transducer (Transonic, Ithaca, NY). The preparation was equilibrated for 10 min and portal pressure continuously recorded for 10 min on a monitor (Transonic BLF 21D, Ithaca, NY) and analyzed using Win Daq software (DATAQ, Akron, OH).

Ethanol-induced gastric damage

Gastric resistance to injury induced by topical application of 40% ethanol was investigated using an *ex vivo* gastric chamber preparation. Rats ($n = 5$ for each group) were anesthetized with sodium pentobarbitone (25-50 mg/kg ip) and placed over a heating pad connected to a rectal probe (Harvard Apparatus, Holliston, MS) to maintain body temperature at 37 °C^[19]. The stomach was exposed following a midline laparotomy and opened with an incision along the greater curvature. It was pinned over a plexiglass platform and clamped with a plexiglass cylinder. This allowed bathing of the mucosa with different solutions. The experiments consisted of six periods of 10 min each. Initially the mucosa was bathed with phosphate buffered saline for two periods, followed by 40% ethanol for one period and then HCl (pH 1.5) for the remaining three periods. All solutions were at 37 °C when added to the chamber and continuously stirred at 200 r/min. The stomach was photographed at the end of experiments and damage measured as % total glandular mucosa using computerized planimetry by an observer blinded to all treatment groups.

Gastric blood flow was measured ($n = 5$ for each group) using laser-Doppler flowmetry and the *ex vivo* gastric chamber preparation. A pencil probe (type N, penetration 1 mm, Transonic, Ithaca, NY) connected to a flowmeter (BLF 21D, Transonic, Ithaca, NY) was placed over the gastric body. The preparation was equilibrated for 5 min. Basal gastric blood flow was then recorded for an additional 5 min, after which the experiments were

started and performed according to the *ex vivo* gastric chamber protocol described previously. Basal gastric blood flow was calculated as average flow over the initial 5 min after equilibration was achieved. Gastric blood flow was then continuously recorded throughout the 60 min experimental protocol and maximum changes in flow at each period were calculated and expressed as % change over basal flow.

Primary sensory afferent neurons, ET receptors, gastric damage and blood flow

Animals were treated on the second day of life with capsaicin (30 mg/kg, sc) or vehicle [10% ethanol and 10% Tween 80 in 0.9% (w/v) NaCl solution], as previously described^[21]. Adult (60 d) vehicle- and capsaicin-pretreated rats ($n > 5$ each) were submitted to BDL or sham operation. *Ex vivo* chamber experiments and measurement of mean arterial and portal pressure were then carried out 4 wk after surgery, as described above. The role of primary sensory afferent neurons and ET receptors was investigated using the systemic administration of the endothelin ET_A and ET_B receptor agonist ET-1 or ET-3 (0.5 nmol/kg, ip) or using a selective ET_A receptor antagonist (BQ 485) or an ET_B receptor antagonist (BQ 788, 0.1 mg/kg, ip) 3 min prior to chamber experiments in vehicle- or capsaicin-treated animals ($n = 5$).

Gastric ET mRNA

Gastric ET-1 and -3 mRNA expression was examined by reverse-transcription polymerase chain reaction (RT-PCR). Samples were collected from the body at the end of chamber experiments. The RNA was isolated using the TRIZOL method and extracted with chloroform after tissue homogenization (GIBCO BRL, Gaithersburg, MD). It was then recovered from the aqueous phase by precipitation with isopropyl alcohol and suspended in DEPC-treated water. cDNA was synthesized from 10 µg of total RNA using 1 µL of reverse transcriptase (MMLV, GIBCO BRL, Gaithersburg, MD). cDNA samples were stored at -20 °C until use. The nucleotide sequence of the primers for ET-1 and ET-3 was the one previously reported in the literature^[22,23]. GAPDH mRNA was the internal control for the PCR reaction. Forty cycles of PCR amplification for ETs isoforms and 33 for GAPDH were chosen following pilot experiments to define amplification conditions. PCR reactions were performed in a final volume of 25 µL containing 2.5 µL cDNA, 2.5 µL 10X Taq buffer, 0.75 µL MgCl₂ (1.5 mmol/L), 0.5 µL dNTPs (0.2 mmol/L), 1.5 µL (0.5 µmol/L) of each oligonucleotide pair (ET-1: GCTCCTGCT CCTCCTTGATG-sense, CTCGCTCTATGTAAGTCATGG-antisense and ET-3 GCTGGTGGACTTTATCTGTCC-sense, TTCTCGGGCTCACAGTGACC-antisense) 15.5 µL H₂O Milli Q and 0.25 µL Taq DNA polymerase (1.25 U). The amplification cycle was done with denaturation for 1 min at 94 °C, annealing for 45 s at 57 °C and extension for 1.5 min at 72 °C for ET1/ET3 isoforms, respectively. The PCR products (10 µL) previously normalized to

give equivalent amounts of the GAPDH control were separated on 1.5% agarose gel containing 10% ethidium bromide. Gels were visualized under UV light and images captured (Chemimager 5500, Alpha-Inotech, San Leandro, CA). The band size for ET-1 and ET-3 was 471 and 477 bp, respectively. Band densitometry was determined to determine the expression of each isoform relative to GAPDH.

Gastric ET-1 and ET-3 production

Gastric samples (0.5 g wet weight, body) were collected from control and BDL rats, homogenized in the presence of aprotinin (10 µg/mL) and stored in a freezer at -80 °C. They were then thawed and centrifuged at 9000 r/min for 20 min (4 °C). The supernatant was collected, acidified with HCl 2 N and applied to sep-pack C18 cartridge (Waters, USA). The adsorbed peptides were eluted and lyophilized. Competitive enzyme immunoassays for ET-1 and ET-3 were conducted according to the manufacturer's guide (Peninsula Laboratories Inc. USA).

Drugs/chemicals

All drugs were of analytical grade or obtained from Sigma (St. Louis, MO), unless otherwise specified.

Statistical analysis

Data are expressed as mean \pm SE and comparisons among groups ($n = 5$) were analyzed by one-way ANOVA, followed by the Student's Newman-Keul's test for multiple comparisons. Statistical significance was considered when $P < 0.05$.

RESULTS

Ethanol-induced injury and gastric blood flow responses in cirrhotic rats

Topical application of ethanol produced a 20% \pm 3% damage to the gastric mucosa in control animals while an significantly increased was observed in BDL rats (76% \pm 4%, $P < 0.001$; Figure 1), with associated flat gastric blood flow responses to the luminal irritant (Figures 1 and 2). This phenomenon was associated with a reduction in gastric blood flow, followed by a hyperemic response when the mucosa was bathed with HCl (Figure 3).

Gastric damage was reduced in BDL and controls after administration of ET-3 or the ET_B receptor antagonist, BQ788 (Figures 1 and 2). The resistance to injury in ET-3 or BQ788 pretreated rats was increased by at least 50% in the BDL group. A significant increase in gastric blood flow after exposure of the gastric mucosa to 40% ethanol was only noted in BDL rats pretreated with the ET_B receptor antagonist (Figure 3). The hyperemic response to ethanol in BQ788-pretreated BDL rats was actually of greater magnitude to that observed in sham-operated controls. ET-1 and the ET_A receptor antagonist BQ485 did not affect either ethanol-induced damage (Figure 1) or gastric blood flow (Figure 3) responses in control or BDL animals.




Figure 1 Ethanol-induced gastric damage in bile duct-ligated rats compared to controls. Gastric damage induced by EtOH-40% was significantly ($P < 0.05$) reduced in bile duct-ligated (BDL) and control rats submitted to endothelin-3 or ET_B receptor antagonist (BQ788) pretreatment, but not after endothelin-1 or ET_A receptor antagonist (BQ485) pretreatment. ^aSignificant difference compared to vehicle-treated control rats ($P < 0.05$).



Figure 2 Gastric damage in bile duct-ligated rats after endothelin-3 and endothelin B receptor antagonist pretreatment. A: Vehicle; B: Endothelin-3; C: BQ788.




Figure 3 Gastric blood flow responses to topical application of 40% ethanol followed by HCl in control and bile duct-ligated rats. ET_B receptor antagonist (BQ788) pretreatment increased significantly ($^aP < 0.05$) the responsiveness of the gastric microcirculation to ethanol followed by the acid solution in bile duct-ligated (BDL) rats, while ET_A receptor antagonist (BQ485) had no changes.

Gastric ET-1 and -3 mRNA

ET-1 mRNA expression was comparable in samples collected from control and BDL rats, while ET-3 mRNA expression was reduced by almost 50% in BDL rats (Figure 4). Ablation of sensory afferent neurons using neonatal treatment with capsaicin produced a significant reduction in ET-1 mRNA expression by the stomach of BDL rats while mRNA expression of ET-3 was detected in levels comparable to controls (Figure 4).

Gastric ET-1 and -3 production

ET-1 and -3 were detected in the stomach of both control and BDL rats. ET-1 was predominant over ET-3 in a 3/1 ratio and its concentration was significantly increased (30% higher, $P < 0.05$) in the stomach of BDL rats compared to controls (data not shown). Ablation of sensory afferent neurons using neonatal capsaicin did produce a significant reduction in gastric ET-1 in the stomach of BDL rats without significantly changing the approximate 3/1 ratio of gastric ET-1/ET-3 detectable (Figure 5). Capsaicin-treated BDL rats had levels of both ET-1 and -3 similar to that found in controls (data not shown).

DISCUSSION

The results of the present study show the interaction of ET through its ET_B receptor in mediating an increased susceptibility to ethanol-induced gastric damage in bile duct ligated, cirrhotic rats.

It has been previously demonstrated that the development of the hyperdynamic circulation in the context of experimental portal hypertension could be prevented by ablation of primary sensory afferent neurons by capsaicin treatment in newborn rats^[19,24]. Capsaicin is the active ingredient of the pungent *capsicum* pepper and when given acutely to adult animals it activates primary afferent nerves, whereas it permanently ablates the same nerves




Figure 4 Gastric endothelin-1 and endothelin-3 expression in control and bile duct-ligated rats relative to the internal housekeeping gene, GAPDH, and expressed as densitometry units. ^aSignificant difference compared to respectively control and bile duct ligation (BDL) vehicle-treated rats ($P < 0.05$).

when given in higher doses neonatally. Ablation of primary afferent neurons in newborn rats has been very useful over the past three decades as a tool to explore the physiology of primary afferent nerves^[25]. For example, we have previously demonstrated the involvement of neuropeptides released from these sensory neurons in the development of portal hypertensive gastropathy^[17,19].

Our data show that ET-3 administration and ET_B receptor blockade result in improved gastric hyperemic response to 40% ethanol in bile duct-ligated rats. This was associated with increased resistance to damage induced by the luminal irritant, whereas ET-1 administration and ET_A receptor blockade had no effect. This suggests once again that the regulation of gastric blood flow responses to a luminal irritant plays a major role in the actual resistance of the gastric mucosa to injury. An impaired microcirculatory response or no changes in mucosal resistance to injury following administration of ET-1 or ET_A receptor antagonist (BQ485) is puzzling and could be secondary to a desensitization of the ET_A receptor to ET-1^[26], but not to ET-3 in BDL rats. Indeed, in our hands, both ET-1 and -3 were detected in the stomach and the concentration was significantly higher in the BDL rats for both isoforms, with an abundance of ET-1 over ET-3. The higher gastric levels of ET-1 could have produced desensitization of the ET_A receptors within the gastric microcirculation by a mechanism of compensatory adaptation to an increased presence of the peptide. All three ET isoforms have similar affinities for the ET_B




Figure 5 Gastric endothelin-1 and -3 synthetic capacity as measured by ELISA. Gastric endothelin (ET)-1 production was increased ($P < 0.05$) in vehicle- relative to capsaicin-treated bile duct ligation (BDL) rats. ^aSignificant difference compared to respective controls ($P < 0.05$).

receptor^[1], but the ET_A receptor binds ET-1 with two- to 10-fold higher affinity than ET-2 and with more than 100-fold higher affinity than ET-3^[22]. Therefore, in our experiments, the observed effects of ET-3 treatment on the gastric hyperemic response to ethanol could be secondary to its action on the ET_A receptor promoting the increase of gastric blood flow in the context of an absent response to ET_A receptor to ET-1. This ultimately increased the resistance of the stomach to injury induced by 40% ethanol in ET-3 treated rats.

ET is a strong stimulus of the release of neuropeptides involved in neurogenic inflammation, such as substance P, CGRP and others. ET may play a role in the repair of damaged neurons^[12,27] and several studies have suggested that ET_A and ET_B receptors are actually expressed in sensory neurons^[1-5]. ET-1 predominates in hepatic^[15] and gastrointestinal systems^[14,28], while ET-3 seems to predominate over ET-1 in neurons of the brain^[29]. Sensory afferent neurons in the stomach, when activated by ethanol or luminal irritants, release CGRP that will ultimately release nitric oxide from the gastric microcirculation, producing the gastric hyperemic response so important in the defence against injury^[18,29]. Again, our results demonstrate an abundance of ET-1 over ET-3 in the stomach, as measured by ELISA in gastric homogenates with a 30% increase in BDL rats compared to controls. Ablation of capsacin sensitive neurons in newborn rats prior to inducing cirrhosis and portal hypertension by BDL restored resistance to injury with associated changes in the gastric hyperemic response in our previous study. The data now presented suggest that capsacin-treated rats had changes in the expression of ET-1 and -3 mRNA, as well as a reduced production of ET-1 by the stomach to levels observed in control, non-cirrhotic rats. Therefore, ablation of sensory afferent neurons by capsacin resulted in improved gastric resistance to injury by reducing the increased production of ETs by the stomach to levels observed in controls. Whether production/release of ETs by other organs/systems within the hyperdynamic circulation BDL rat model also contributes to what we demonstrated in this study is

unclear, was not the goal of this study and remains to be elucidated.

The results of this study suggest that sensory afferent neurons are an integral component of the regulatory mechanisms associated with the gastric hyperemic response to luminal irritants and its effects on mucosal resistance to injury. ET production is modulated by the primary afferent neurons and one could speculate that ET-1 may actually promote tachykinin release from afferent neurons. In turn, binding of released tachykinins (for example, Substance P) to their tachykinin receptor 1 (NK1) on endothelial cells within the gastric microcirculation leads to the final response of increased blood flow by nitric oxide release, namely the gastric hyperemic response. As such, ET-1 could potentially negatively affect gastric mucosal defence in the portal hypertensive gastropathy *via* ET_B receptor activation as ET_B is expressed in sensory neurons that promote tachykinin release when activated. Furthermore, as demonstrated by our study, ET-3 treatment produced a reduction in ethanol-induced gastric damage in BDL rats; an effect that was also seen with ET_B receptors blocked using BQ-788.

Our results support the notion that studies evaluating the potential role of ET_B receptor agonists as well as ET-3 in the treatment of portal hypertensive gastropathy in humans are warranted. The gastric concentration of ET is increased in the stomach of BDL rats, a model of cirrhosis and portal hypertension and its receptors modulate the gastric hyperemic response to topical application of ethanol with consequent impact on the resistance to injury induced by the luminal irritant.

COMMENTS

Background

Increased resistance to portal blood flow in the context of liver dysfunction leading to portal hypertension increases the risk of bleeding episodes in cirrhotic patients. It would be helpful to develop strategies to reduce the risk of bleeding in these patients.

Research frontiers

Endothelin (ET) has been explored in both basic and clinical research. They play a role in gastric resistance to injury in the bile duct ligation (BDL) model of cirrhosis and portal hypertension in rats. ET production can be modulated by sensory afferent neurons. The effects of ET receptor agonists and antagonists along with ablation of sensory afferent neurons on the resistance of the stomach and the gastric blood flow responses to 40% ethanol were investigated in an effort to integrate the defence mechanisms employed by the stomach in the context of experimental cirrhosis.

Innovations and breakthroughs

Ethanol-induced gastric damage was reduced using an ET-3 agonist and an ET_B receptor antagonist in BDL rats. Ablation of sensory afferent neurons by capsaicin in newborn rats restored the gastric resistance to ethanol-induced injury with normalization of gastric ET-1 and -3 synthesis and improved hyperemic response to the topical irritant.

Applications

The present study supports the concept that ET-1 and -3 should be investigated in the clinical setting, along with the use of an ET-3 agonist or ET_B receptor antagonist. The use of this strategy is warranted in the context of liver cirrhosis, portal hypertension and portal hypertensive gastropathy.

Terminology

Portal hypertensive gastropathy is a complication found in patients with liver cirrhosis and portal hypertension. It can be associated with clinically significant

acute or chronic bleeding episodes. BDL is an experimental model of secondary biliary cirrhosis, liver dysfunction, portal hypertension and ascites, similar to that found in patients with cirrhosis. ET is a family of peptides for experimental use.

Peer review


This is a study in which the authors analyze the integration between ET and sensory afferent neurons on gastric damage induced by ethanol in rats. The results suggest that an ET_B receptor antagonist and ET-3 could be tested in the clinical setting with a goal of increasing the gastric resistance to injury in the context of liver cirrhosis and portal hypertension.

REFERENCES

- 1 **Pomonis JD**, Rogers SD, Peters CM, Ghilardi JR, Mantyh PW. Expression and localization of endothelin receptors: implications for the involvement of peripheral glia in nociception. *J Neurosci* 2001; **21**: 999-1006
- 2 **Ritz MF**, Stuenkel EL, Dayanithi G, Jones R, Nordmann JJ. Endothelin regulation of neuropeptide release from nerve endings of the posterior pituitary. *Proc Natl Acad Sci USA* 1992; **89**: 8371-8375
- 3 **Gokin AP**, Fareed MU, Pan HL, Hans G, Strichartz GR, Davar G. Local injection of endothelin-1 produces pain-like behavior and excitation of nociceptors in rats. *J Neurosci* 2001; **21**: 5358-5366
- 4 **Dogulu FH**, Ozogul C, Akpek S, Kurt G, Emmez H, Ercan S, Baykaner MK. Intra-arterial simultaneous administration of anandamide attenuates endothelin-1 induced vasospasm in rabbit basilar arteries. *Acta Neurochir (Wien)* 2003; **145**: 579-582
- 5 **Zhou QL**, Strichartz G, Davar G. Endothelin-1 activates ET(A) receptors to increase intracellular calcium in model sensory neurons. *Neuroreport* 2001; **12**: 3853-3857
- 6 **Calvo JJ**, Gonzalez R, De Carvalho LF, Takahashi K, Kanse SM, Hart GR, Ghatei MA, Bloom SR. Release of substance P from rat hypothalamus and pituitary by endothelin. *Endocrinology* 1990; **126**: 2288-2295
- 7 **Dymshitz J**, Vasko MR. Endothelin-1 enhances capsaicin-induced peptide release and cGMP accumulation in cultures of rat sensory neurons. *Neurosci Lett* 1994; **167**: 128-132
- 8 **Wang DH**. The vanilloid receptor and hypertension. *Acta Pharmacol Sin* 2005; **26**: 286-294
- 9 **Brändli P**, Löffler BM, Breu V, Osterwalder R, Maire JP, Clozel M. Role of endothelin in mediating neurogenic plasma extravasation in rat dura mater. *Pain* 1996; **64**: 315-322
- 10 **Germonpre PR**, Bullock GR, Lambrecht BN, Van De Velde V, Luyten WH, Joos GF, Pauwels RA. Presence of substance P and neurokinin 1 receptors in human sputum macrophages and U-937 cells. *Eur Respir J* 1999; **14**: 776-782
- 11 **D'Agostino B**, Advenier C, Falciani M, Gallelli L, Marrocco G, Piegari E, Filippelli A, Rossi F. Endothelin-1 increases cholinergic nerve-mediated contraction of human bronchi via tachykinin synthesis induction. *Br J Pharmacol* 2001; **134**: 1447-1454
- 12 **Milner P**, Loesch A, Burnstock G. Endothelin immunoreactivity and mRNA expression in sensory and sympathetic neurones following selective denervation. *Int J Dev Neurosci* 2000; **18**: 727-734
- 13 **Takahashi K**, Jones PM, Kanse SM, Lam HC, Spokes RA, Ghatei MA, Bloom SR. Endothelin in the gastrointestinal tract. Presence of endothelinlike immunoreactivity, endothelin-1 messenger RNA, endothelin receptors, and pharmacological effect. *Gastroenterology* 1990; **99**: 1660-1667
- 14 **Ohta M**, Pai R, Kawanaka H, Ma T, Sugimachi K, Sarfeh IJ, Tarnawski AS. Expression of endothelin-1, and endothelin A and B receptors in portal hypertensive esophagus of rats. *J Physiol Pharmacol* 2000; **51**: 57-67
- 15 **Gandhi CR**, Stephenson K, Olson MS. Endothelin, a potent peptide agonist in the liver. *J Biol Chem* 1990; **265**:

- 17432-17435
- 16 **Beck PL**, Lee SS, McKnight GW, Wallace JL. Characterization of spontaneous and ethanol-induced gastric damage in cirrhotic rats. *Gastroenterology* 1992; **103**: 1048-1055
- 17 **Ferraz JG**, McKnight W, Sharkey KA, Wallace JL. Impaired vasodilatory responses in the gastric microcirculation of anesthetized rats with secondary biliary cirrhosis. *Gastroenterology* 1995; **108**: 1183-1191
- 18 **Geraldo J**, Ferraz P, Wallace JL. Prostaglandins modulate the responsiveness of the gastric microcirculation of sodium nitroprusside in cirrhotic rats. *Hepatology* 1996; **23**: 123-129
- 19 **Camara PR**, Ferraz GJ, Franco-Penteado CF, Sbragia-Neto L, Meirelles LR, Teixeira SA, Muscara MN, Velloso LA, Antunes E, Ferraz JG. Ablation of primary afferent neurons by neonatal capsaicin treatment reduces the susceptibility of the portal hypertensive gastric mucosa to ethanol-induced injury in cirrhotic rats. *Eur J Pharmacol* 2008; **589**: 245-250
- 20 **Câmara PR**, Moi GP, Ferraz JG, Zeitune JM. Effect of anesthetics on gastric damage using two models of portal hypertension. *World J Gastrointest Pharmacol Ther* 2010; **1**: 81-86
- 21 **Jancsó G**, Kiraly E, Jancsó-Gábor A. Pharmacologically induced selective degeneration of chemosensitive primary sensory neurones. *Nature* 1977; **270**: 741-743
- 22 **David FL**, Montezano AC, Rebouças NA, Nigro D, Fortes ZB, Carvalho MH, Tostes RC. Gender differences in vascular expression of endothelin and ET(A)/ET(B) receptors, but not in calcium handling mechanisms, in deoxycorticosterone acetate-salt hypertension. *Braz J Med Biol Res* 2002; **35**: 1061-1068
- 23 **Terada Y**, Tomita K, Nonoguchi H, Yang T, Marumo F. Expression of endothelin-3 mRNA along rat nephron segments using polymerase chain reaction. *Kidney Int* 1993; **44**: 1273-1280
- 24 **Li Y**, Song D, Zhang Y, Lee SS. Effect of neonatal capsaicin treatment on haemodynamics and renal function in cirrhotic rats. *Gut* 2003; **52**: 293-299
- 25 **Caterina MJ**, Julius D. The vanilloid receptor: a molecular gateway to the pain pathway. *Annu Rev Neurosci* 2001; **24**: 487-517
- 26 **Thakali K**, Fink GD, Watts SW. Arteries and veins desensitize differently to endothelin. *J Cardiovasc Pharmacol* 2004; **43**: 387-393
- 27 **Milner P**, Bodin P, Guiducci S, Del Rosso A, Kahaleh MB, Matucci-Cerinic M, Burnstock G. Regulation of substance P mRNA expression in human dermal microvascular endothelial cells. *Clin Exp Rheumatol* 2004; **22**: S24-S27
- 28 **Migoh S**, Hashizume M, Tsugawa K, Tanoue K, Sugimachi K. Role of endothelin-1 in congestive gastropathy in portal hypertensive rats. *J Gastroenterol Hepatol* 2000; **15**: 142-147
- 29 **Tepperman BL**, Whittle BJ. Endogenous nitric oxide and sensory neuropeptides interact in the modulation of the rat gastric microcirculation. *Br J Pharmacol* 1992; **105**: 171-175

S- Editor Zhai HH **L- Editor** Roemmele A **E- Editor** Zheng XM



ACKNOWLEDGMENTS

Acknowledgments to reviewers of World Journal of Gastrointestinal Pathophysiology

We acknowledge our sincere thanks to our reviewers. Many reviewers have contributed their expertise and time to the peer review, a critical process to ensure the quality of our World Series Journals. Both the editors of the journals and authors of the manuscripts submitted to the journals are grateful to the following reviewers for reviewing the articles (either published or rejected) over the past period of time.

Dr. Marco Bustamante, Department of Gastroenterology, La Fe University Hospital, Avda. Gaspar Aguilar, 90, Valencia 46017, Spain

Julio Chebli, Professor, Department of Medicine, Federal University of Juiz de Fora, Maria Jose Leal, 296, Juiz de Fora 36036247, Brazil

Enzo Ierardi, Professor, Department of Medical Sciences, Section of Gastroenterology, University Gastroenterology Unit, AOU Ospedali Riuniti, 71100 Foggia, Italy

Leo Fitzpatrick, Associate Professor, Penn State College of Medicine, 1214 Research Boulevard, Hummelstown, PA 17036, United States

Mitsunori Yamakawa, Professor, Department of Pathological Diagnostics, Faculty of Medicine, Yamagata University, 2-2-2 Iida-Nishi, Yamagata 990-9585, Japan

Takayuki Yamamoto, MD, PhD, FACG, Inflammatory Bowel Disease Center, Yokkaichi Social Insurance Hospital, 10-8 Hazuyamacho, Yokkaichi 510-0016, Japan



Events Calendar 2012

February 14-15, 2012 3rd World Congress of Laparoscopic Surgeons and Gynecologists Delhi, India	May 1-4, 2012 19th International Surgical Pathology Symposium Zagreb, Croatia
February 15-18, 2012 23rd Annual International Colorectal Disease Symposium Fort Lauderdale, FL, United States	May 19-22, 2012 Digestive Disease Week 2012 San Diego, CA, United States
February 16-18, 2012 7th Congress of ECCO Barcelona, Spain	June 20-23, 2012 European Association for Endoscopic Surgery 20th International Congress 2012 Brussels, Belgium
February 21-23, 2012 International Scientific Conference on Bacteriocins and Antimicrobial Peptides - BAMP2012 Kosice, Slovakia	June 23- 27, 2012 International Society of University Colon and Rectal Surgeons 25th Biennial Conference 2012 Bologna, Italy
February 24-26, 2012 Advances in Hepato Biliary Pancreatic Endoscopy Hyderabad, India	October 10-13, 2012 ISPAD 2012 - 38th Annual Meeting International Society for Pediatric and Adolescent Diabetes Istanbul, Turkey
February 25-March 2, 2012 29th AGC Course 2012, 29th International Gastrointestinal Surgery Workshop Lupsingen, Switzerland	October 15-17, 2012 13th World Congress of the International Society for Diseases of the Esophagus Venice, Italy
March 13-16, 2012 12th Annual Gastroenterology and Hepatology: Viva la Vida San Juan, Puerto Rico	October 18-20, 2012 Kongress Essstörungen 2012/Eating Disorders Alpbach 2012 The 20th International Conference Tyrol, Austria
March 1-4, 2012 Mayo Clinic 2012 Gastroenterology and Hepatology Coronado, CA, United States	October 20-24, 2012 UEGW - 20th United European Gastroenterology Week Amsterdam, The Netherlands
March 22-24, 2012 1st Gallen EORTC Gastrointestinal Cancer Conference: Primary Therapy of Early GI Cancer with International Treatment Consensus St Gallen, Switzerland	November 3-4, 2012 Modern technologies in diagnosis and treatment of gastroenterological patients Dnepropetrovsk, Ukraine
March 1-3, 2012 International conference on nutrition and growth Paris, France	November 14-15, 2012 The Third Announcement of WCPGHAN 2012! Taipei, Taiwan, China



GENERAL INFORMATION

World Journal of Gastrointestinal Pathophysiology (World J Gastrointest Pathophysiol, WJGP, online ISSN 2150-5330, DOI: 10.4291), is a bimonthly, open-access (OA), peer-reviewed journal supported by an editorial board of 296 experts in gastrointestinal pathophysiology from 39 countries.

The biggest advantage of the OA model is that it provides free, full-text articles in PDF and other formats for experts and the public without registration, which eliminates the obstacle that traditional journals possess and usually delays the speed of the propagation and communication of scientific research results.

Maximization of personal benefits

The role of academic journals is to exhibit the scientific levels of a country, a university, a center, a department, and even a scientist, and build an important bridge for communication between scientists and the public. As we all know, the significance of the publication of scientific articles lies not only in disseminating and communicating innovative scientific achievements and academic views, as well as promoting the application of scientific achievements, but also in formally recognizing the "priority" and "copyright" of innovative achievements published, as well as evaluating research performance and academic levels. So, to realize these desired attributes of WJGP and create a well-recognized journal, the following four types of personal benefits should be maximized. The maximization of personal benefits refers to the pursuit of the maximum personal benefits in a well-considered optimal manner without violation of the laws, ethical rules and the benefits of others. (1) Maximization of the benefits of editorial board members: The primary task of editorial board members is to give a peer review of an unpublished scientific article *via* online office system to evaluate its innovativeness, scientific and practical values and determine whether it should be published or not. During peer review, editorial board members can also obtain cutting-edge information in that field at first hand. As leaders in their field, they have priority to be invited to write articles and publish commentary articles. We will put peer reviewers' names and affiliations along with the article they reviewed in the journal to acknowledge their contribution; (2) Maximization of the benefits of authors: Since WJGP is an OA journal, readers around the world can immediately download and read, free of charge, high-quality, peer-reviewed articles from WJGP official website, thereby realizing the goals and significance of the communication between authors and peers as well as public reading; (3) Maximization of the benefits of readers: Readers can read or use, free of charge, high-quality peer-reviewed articles without any limits, and cite the arguments, viewpoints, concepts, theories, methods, results, conclusion or facts and data of pertinent literature so as to validate the innovativeness, scientific and practical values of their own research achievements, thus ensuring that their articles have novel arguments or viewpoints, solid evidence and correct conclusion; and (4) Maximization of the benefits of employees: It is an iron law that a first-class journal is unable to exist without first-class editors, and only first-class editors can create a first-class academic journal. We insist on strengthening our team cultivation and construction so that every employee, in an open, fair

and transparent environment, could contribute their wisdom to edit and publish high-quality articles, thereby realizing the maximization of the personal benefits of editorial board members, authors and readers, and yielding the greatest social and economic benefits.

Aims and scope

The major task of WJGP is to report rapidly the most recent results in basic and clinical research on gastrointestinal pathophysiology, including all aspects of normal or abnormal function of the gastrointestinal tract, hepatobiliary system, and pancreas. WJGP specifically covers growth and development, digestion, secretion, absorption, metabolism and motility relative to the gastrointestinal organs, as well as immune and inflammatory processes, and neural, endocrine and circulatory control mechanisms that affect these organs. This journal will also report new methods and techniques in gastrointestinal pathophysiological research.

Columns

The columns in the issues of WJGP will include: (1) Editorial: To introduce and comment on major advances and developments in the field; (2) Frontier: To review representative achievements, comment on the state of current research, and propose directions for future research; (3) Topic Highlight: This column consists of three formats, including (A) 10 invited review articles on a hot topic, (B) a commentary on common issues of this hot topic, and (C) a commentary on the 10 individual articles; (4) Observation: To update the development of old and new questions, highlight unsolved problems, and provide strategies on how to solve the questions; (5) Guidelines for Basic Research: To provide guidelines for basic research; (6) Guidelines for Clinical Practice: To provide guidelines for clinical diagnosis and treatment; (7) Review: To review systemically progress and unresolved problems in the field, comment on the state of current research, and make suggestions for future work; (8) Original Articles: To report innovative and original findings in gastrointestinal pathophysiology; (9) Brief Articles: To briefly report the novel and innovative findings in gastrointestinal pathophysiology; (10) Case Report: To report a rare or typical case; (11) Letters to the Editor: To discuss and make reply to the contributions published in WJGP, or to introduce and comment on a controversial issue of general interest; (12) Book Reviews: To introduce and comment on quality monographs of gastrointestinal pathophysiology; and (13) Guidelines: To introduce consensus and guidelines reached by international and national academic authorities worldwide on basic research and clinical practice in gastrointestinal pathophysiology.

Name of journal

World Journal of Gastrointestinal Pathophysiology

ISSN

ISSN 2150-5330 (online)

Editor-in-chief

Thomas Y Ma, MD, PhD, Professor, Chief, Division of Gastroenterology and Hepatology, University of New Mexico, MSC10 5550, 1 UNM, Albuquerque, NM 87131, United States

Instructions to authors

Editorial office

World Journal of Gastrointestinal Pathophysiology
Editorial Department: Room 903, Building D,
Ocean International Center,
No. 62 Dongsihuan Zhonglu,
Chaoyang District, Beijing 100025, China
E-mail: wjgp@wjgnet.com
<http://www.wjgnet.com>
Telephone: +86-10-85381892
Fax: +86-10-8538-1893

Indexed/abstracted in

PubMed Central, PubMed, Digital Object Identifier, and Directory of Open Access Journals.

Published by

Baishideng Publishing Group Co., Limited

SPECIAL STATEMENT

All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

Biostatistical editing

Statistical review is performed after peer review. We invite an expert in Biomedical Statistics to evaluate the statistical method used in the paper, including *t*-test (group or paired comparisons), chi-squared test, Redit, probit, logit, regression (linear, curvilinear, or stepwise), correlation, analysis of variance, analysis of covariance, *etc.* The reviewing points include: (1) Statistical methods should be described when they are used to verify the results; (2) Whether the statistical techniques are suitable or correct; (3) Only homogeneous data can be averaged. Standard deviations are preferred to standard errors. Give the number of observations and subjects (*n*). Losses in observations, such as drop-outs from the study should be reported; (4) Values such as ED50, LD50, IC50 should have their 95% confidence limits calculated and compared by weighted probit analysis (Bliss and Finney); and (5) The word 'significantly' should be replaced by its synonyms (if it indicates extent) or the *P* value (if it indicates statistical significance).

Conflict-of-interest statement

In the interests of transparency and to help reviewers assess any potential bias, *WJGP* requires authors of all papers to declare any competing commercial, personal, political, intellectual, or religious interests in relation to the submitted work. Referees are also asked to indicate any potential conflict they might have reviewing a particular paper. Before submitting, authors are suggested to read "Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Ethical Considerations in the Conduct and Reporting of Research: Conflicts of Interest" from International Committee of Medical Journal Editors (ICMJE), which is available at: http://www.icmje.org/ethical_4conflicts.html.

Sample wording: [Name of individual] has received fees for serving as a speaker, a consultant and an advisory board member for [names of organizations], and has received research funding from [names of organization]. [Name of individual] is an employee of [name of organization]. [Name of individual] owns stocks and shares in [name of organization]. [Name of individual] owns patent [patent identification and brief description].

Statement of informed consent

Manuscripts should contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee or it should be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted. Authors should also draw attention to the Code of Ethics of the World Medical Association (Declaration of Helsinki, 1964, as revised in 2004).

Statement of human and animal rights

When reporting the results from experiments, authors should follow the highest standards and the trial should conform to Good Clinical Practice (for example, US Food and Drug Administration Good Clinical Practice in FDA-Regulated Clinical Trials; UK Medicines Research Council Guidelines for Good Clinical Practice in Clinical Trials) and/or the World Medical Association Declaration of Helsinki. Generally, we suggest authors follow the lead investigator's national standard. If doubt exists whether the research was conducted in accordance with the above standards, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study.

Before submitting, authors should make their study approved by the relevant research ethics committee or institutional review board. If human participants were involved, manuscripts must be accompanied by a statement that the experiments were undertaken with the understanding and appropriate informed consent of each. Any personal item or information will not be published without explicit consents from the involved patients. If experimental animals were used, the materials and methods (experimental procedures) section must clearly indicate that appropriate measures were taken to minimize pain or discomfort, and details of animal care should be provided.

SUBMISSION OF MANUSCRIPTS

Manuscripts should be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Number all pages consecutively, and start each of the following sections on a new page: Title Page, Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgements, References, Tables, Figures, and Figure Legends. Neither the editors nor the publisher are responsible for the opinions expressed by contributors. Manuscripts formally accepted for publication become the permanent property of Baishideng Publishing Group Co., Limited, and may not be reproduced by any means, in whole or in part, without the written permission of both the authors and the publisher. We reserve the right to copy-edit and put onto our website accepted manuscripts. Authors should follow the relevant guidelines for the care and use of laboratory animals of their institution or national animal welfare committee. For the sake of transparency in regard to the performance and reporting of clinical trials, we endorse the policy of the International Committee of Medical Journal Editors to refuse to publish papers on clinical trial results if the trial was not recorded in a publicly-accessible registry at its outset. The only register now available, to our knowledge, is <http://www.clinicaltrials.gov> sponsored by the United States National Library of Medicine and we encourage all potential contributors to register with it. However, in the case that other registers become available you will be duly notified. A letter of recommendation from each author's organization should be provided with the contributed article to ensure the privacy and secrecy of research is protected.

Authors should retain one copy of the text, tables, photographs and illustrations because rejected manuscripts will not be returned to the author(s) and the editors will not be responsible for loss or damage to photographs and illustrations sustained during mailing.

Online submissions

Manuscripts should be submitted through the Online Submission System at: <http://www.wjgnet.com/esps/>. Authors are highly recommended to consult the ONLINE INSTRUCTIONS TO AUTHORS (http://www.wjgnet.com/2150-5330/g_info_20100316080008.htm) before attempting to submit online. For assistance, authors encountering problems with the Online Submission System may send an email describing the problem to wjgp@wjgnet.com, or by telephone: +86-10-59080038. If you submit your manuscript online, do not make a postal contribution. Repeated online submission for the

same manuscript is strictly prohibited.

MANUSCRIPT PREPARATION

All contributions should be written in English. All articles must be submitted using word-processing software. All submissions must be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Style should conform to our house format. Required information for each of the manuscript sections is as follows:

Title page

Title: Title should be less than 12 words.

Running title: A short running title of less than 6 words should be provided.

Authorship: Authorship credit should be in accordance with the standard proposed by International Committee of Medical Journal Editors, based on (1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3.

Institution: Author names should be given first, then the complete name of institution, city, province and postcode. For example, Xu-Chen Zhang, Li-Xin Mei, Department of Pathology, Chengde Medical College, Chengde 067000, Hebei Province, China. One author may be represented from two institutions, for example, George Sgourakis, Department of General, Visceral, and Transplantation Surgery, Essen 45122, Germany; George Sgourakis, 2nd Surgical Department, Korgialenio-Benakio Red Cross Hospital, Athens 15451, Greece.

Author contributions: The format of this section should be: Author contributions: Wang CL and Liang L contributed equally to this work; Wang CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the research; Wang CL, Zou CC, Hong F and Wu XM performed the research; Xue JZ and Lu JR contributed new reagents/analytic tools; Wang CL, Liang L and Fu JF analyzed the data; and Wang CL, Liang L and Fu JF wrote the paper.

Supportive foundations: The complete name and number of supportive foundations should be provided, e.g., Supported by National Natural Science Foundation of China, No. 30224801.

Correspondence to: Only one corresponding address should be provided. Author names should be given first, then author title, affiliation, the complete name of institution, city, postcode, province, country, and email. All the letters in the email should be in lower case. A space interval should be inserted between country name and email address. For example, Montgomery Bissell, MD, Professor of Medicine, Chief, Liver Center, Gastroenterology Division, University of California, Box 0538, San Francisco, CA 94143, United States. montgomery.bissell@ucsf.edu

Telephone and fax: Telephone and fax should consist of +, country number, district number and telephone or fax number, e.g., Telephone: +86-10-59080039 Fax: +86-10-85381893

Peer reviewers: All articles received are subject to peer review. Normally, three experts are invited for each article. Decision for acceptance is made only when at least two experts recommend an article for publication. Reviewers for accepted manuscripts are acknowledged in each manuscript, and reviewers of articles which were not accepted will be acknowledged at the end of each issue. To ensure the quality of the articles published in *WJGP*, reviewers of accepted manuscripts will be announced by publishing the name, title/position and institution of the re-

viewer in the footnote accompanying the printed article. For example, reviewers: Professor Jing-Yuan Fang, Shanghai Institute of Digestive Disease, Shanghai, Affiliated Renji Hospital, Medical Faculty, Shanghai Jiaotong University, Shanghai, China; Professor Xin-Wei Han, Department of Radiology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan Province, China; and Professor Anren Kuang, Department of Nuclear Medicine, Huaxi Hospital, Sichuan University, Chengdu, Sichuan Province, China.

Abstract

There are unstructured abstracts (no less than 256 words) and structured abstracts (no less than 480). The specific requirements for structured abstracts are as follows:

An informative, structured abstracts of no more less 480 words should accompany each manuscript. Abstracts for original contributions should be structured into the following sections. AIM (no more than 20 words): Only the purpose should be included. Please write the aim as the form of "To investigate/study/...; MATERIALS AND METHODS (no less than 140 words); RESULTS (no less than 294 words): You should present *P* values where appropriate and must provide relevant data to illustrate how they were obtained, e.g. 6.92 ± 3.86 vs 3.61 ± 1.67 , $P < 0.001$; CONCLUSION (no more than 26 words).

Key words

Please list 5-10 key words, selected mainly from *Index Medicus*, which reflect the content of the study.

Text

For articles of these sections, original articles, rapid communication and case reports, the main text should be structured into the following sections: INTRODUCTION, MATERIALS AND METHODS, RESULTS and DISCUSSION, and should include appropriate Figures and Tables. Data should be presented in the main text or in Figures and Tables, but not in both. The main text format of these sections, editorial, topic highlight, case report, letters to the editors, can be found at: http://www.wjgnet.com/2150-5330/g_info_20100316080000.htm.

Illustrations

Figures should be numbered as 1, 2, 3, *etc.*, and mentioned clearly in the main text. Provide a brief title for each figure on a separate page. Detailed legends should not be provided under the figures. This part should be added into the text where the figures are applicable. Figures should be either Photoshop or Illustrator files (in tiff, eps, jpeg formats) at high-resolution. Examples can be found at: <http://www.wjgnet.com/1007-9327/13/4520.pdf>; <http://www.wjgnet.com/1007-9327/13/4554.pdf>; <http://www.wjgnet.com/1007-9327/13/4891.pdf>; <http://www.wjgnet.com/1007-9327/13/4986.pdf>; <http://www.wjgnet.com/1007-9327/13/4498.pdf>. Keeping all elements compiled is necessary in line-art image. Scale bars should be used rather than magnification factors, with the length of the bar defined in the legend rather than on the bar itself. File names should identify the figure and panel. Avoid layering type directly over shaded or textured areas. Please use uniform legends for the same subjects. For example: Figure 1 Pathological changes in atrophic gastritis after treatment. A: ...; B: ...; C: ...; D: ...; E: ...; F: ...; G: ...*etc.* It is our principle to publish high resolution-figures for the printed and E-versions.

Tables

Three-line tables should be numbered 1, 2, 3, *etc.*, and mentioned clearly in the main text. Provide a brief title for each table. Detailed legends should not be included under tables, but rather added into the text where applicable. The information should complement, but not duplicate the text. Use one horizontal line under the title, a second under column heads, and a third below the Table, above any footnotes. Vertical and italic lines should be omitted.

Notes in tables and illustrations

Data that are not statistically significant should not be noted.

Instructions to authors

^a $P < 0.05$, ^b $P < 0.01$ should be noted ($P > 0.05$ should not be noted). If there are other series of P values, ^c $P < 0.05$ and ^d $P < 0.01$ are used. A third series of P values can be expressed as ^e $P < 0.05$ and ^f $P < 0.01$. Other notes in tables or under illustrations should be expressed as ¹F, ²F, ³F; or sometimes as other symbols with a superscript (Arabic numerals) in the upper left corner. In a multi-curve illustration, each curve should be labeled with ●, ○, ■, □, ▲, △, etc., in a certain sequence.

Acknowledgments

Brief acknowledgments of persons who have made genuine contributions to the manuscript and who endorse the data and conclusions should be included. Authors are responsible for obtaining written permission to use any copyrighted text and/or illustrations.

REFERENCES

Coding system

The author should number the references in Arabic numerals according to the citation order in the text. Put reference numbers in square brackets in superscript at the end of citation content or after the cited author's name. For citation content which is part of the narration, the coding number and square brackets should be typeset normally. For example, "Crohn's disease (CD) is associated with increased intestinal permeability^[1,2]". If references are cited directly in the text, they should be put together within the text, for example, "From references^[19,22-24], we know that..."

When the authors write the references, please ensure that the order in text is the same as in the references section, and also ensure the spelling accuracy of the first author's name. Do not list the same citation twice.

PMID and DOI

Please provide PubMed citation numbers to the reference list, e.g. PMID and DOI, which can be found at <http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed> and <http://www.crossref.org/SimpleTextQuery/>, respectively. The numbers will be used in E-version of this journal.

Style for journal references

Authors: the name of the first author should be typed in bold-faced letters. The family name of all authors should be typed with the initial letter capitalized, followed by their abbreviated first and middle initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR). The title of the cited article and italicized journal title (journal title should be in its abbreviated form as shown in PubMed), publication date, volume number (in black), start page, and end page [PMID: 11819634 DOI: 10.3748/wjg.13.5396].

Style for book references

Authors: the name of the first author should be typed in bold-faced letters. The surname of all authors should be typed with the initial letter capitalized, followed by their abbreviated middle and first initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR) Book title. Publication number. Publication place: Publication press, Year: start page and end page.

Format

Journals

English journal article (list all authors and include the PMID where applicable)

- 1 **Jung EM**, Clevert DA, Schreyer AG, Schmitt S, Rennert J, Kubale R, Feuerbach S, Jung F. Evaluation of quantitative contrast harmonic imaging to assess malignancy of liver tumors: A prospective controlled two-center study. *World J Gastroenterol* 2007; **13**: 6356-6364 [PMID: 18081224 DOI: 10.3748/wjg.13.6356]

Chinese journal article (list all authors and include the PMID where applicable)

- 2 **Lin GZ**, Wang XZ, Wang P, Lin J, Yang FD. Immunologic

effect of Jianpi Yishen decoction in treatment of Pixu-diarrrhoea. *Shijie Huaren Xiaobua Zazhi* 1999; **7**: 285-287

In press

- 3 **Tian D**, Araki H, Stahl E, Bergelson J, Kreitman M. Signature of balancing selection in Arabidopsis. *Proc Natl Acad Sci USA* 2006; In press

Organization as author

- 4 **Diabetes Prevention Program Research Group**. Hyper tension, insulin, and proinsulin in participants with impaired glucose tolerance. *Hypertension* 2002; **40**: 679-686 [PMID: 12411462 PMCID:2516377 DOI:10.1161/01.HYP.0000035706.28494.09]

Both personal authors and an organization as author

- 5 **Vallancien G**, Emberton M, Harving N, van Moorselaar RJ; Alf-One Study Group. Sexual dysfunction in 1, 274 European men suffering from lower urinary tract symptoms. *J Urol* 2003; **169**: 2257-2261 [PMID: 12771764 DOI:10.1097/01.ju.0000067940.76090.73]

No author given

- 6 21st century heart solution may have a sting in the tail. *BMJ* 2002; **325**: 184 [PMID: 12142303 DOI:10.1136/bmj.325.7357.184]

Volume with supplement

- 7 **Geraud G**, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. *Headache* 2002; **42** Suppl 2: S93-99 [PMID: 12028325 DOI:10.1046/j.1526-4610.42.s2.7.x]

Issue with no volume

- 8 **Banit DM**, Kaufer H, Hartford JM. Intraoperative frozen section analysis in revision total joint arthroplasty. *Clin Orthop Relat Res* 2002; **(401)**: 230-238 [PMID: 12151900 DOI:10.1097/00003086-200208000-00026]

No volume or issue

- 9 Outreach: Bringing HIV-positive individuals into care. *HRS A Careaction* 2002; 1-6 [PMID: 12154804]

Books

Personal author(s)

- 10 **Sherlock S**, Dooley J. Diseases of the liver and biliary system. 9th ed. Oxford: Blackwell Sci Pub, 1993: 258-296

Chapter in a book (list all authors)

- 11 **Lam SK**. Academic investigator's perspectives of medical treatment for peptic ulcer. In: Swabb EA, Azabo S. Ulcer disease: investigation and basis for therapy. New York: Marcel Dekker, 1991: 431-450

Author(s) and editor(s)

- 12 **Breedlove GK**, Schorfheide AM. Adolescent pregnancy. 2nd ed. Wicczorek RR, editor. White Plains (NY): March of Dimes Education Services, 2001: 20-34

Conference proceedings

- 13 **Harnden P**, Joffe JK, Jones WG, editors. Germ cell tumours V. Proceedings of the 5th Germ cell tumours Conference; 2001 Sep 13-15; Leeds, UK. New York: Springer, 2002: 30-56

Conference paper

- 14 **Christensen S**, Oppacher F. An analysis of Koza's computational effort statistic for genetic programming. In: Foster JA, Lutton E, Miller J, Ryan C, Tettamanzi AG, editors. Genetic programming. EuroGP 2002: Proceedings of the 5th European Conference on Genetic Programming; 2002 Apr 3-5; Kinsdale, Ireland. Berlin: Springer, 2002: 182-191

Electronic journal (list all authors)

- 15 Morse SS. Factors in the emergence of infectious diseases. *Emerg Infect Dis* serial online, 1995-01-03, cited 1996-06-05; 1(1): 24 screens. Available from: URL: <http://www.cdc.gov/ncidod/eid/index.htm>

Patent (list all authors)

- 16 **Pagedas AC**, inventor; Ancel Surgical R&D Inc., assignee. Flexible endoscopic grasping and cutting device and positioning tool assembly. United States patent US 20020103498. 2002 Aug 1

Statistical data

Write as mean \pm SD or mean \pm SE.

Statistical expression

Express *t* test as *t* (in italics), *F* test as *F* (in italics), chi square test as χ^2 (in Greek), related coefficient as *r* (in italics), degree of freedom as ν (in Greek), sample number as *n* (in italics), and probability as *P* (in italics).

Units

Use SI units. For example: body mass, *m* (B) = 78 kg; blood pressure, *p* (B) = 16.2/12.3 kPa; incubation time, *t* (incubation) = 96 h; blood glucose concentration, *c* (glucose) 6.4 ± 2.1 mmol/L; blood CEA mass concentration, *p* (CEA) = 8.6 $24.5 \mu\text{g/L}$; CO₂ volume fraction, 50 mL/L CO₂, not 5% CO₂; likewise for 40 g/L formaldehyde, not 10% formalin; and mass fraction, 8 ng/g, *etc.* Arabic numerals such as 23, 243, 641 should be read 23 243 641.

The format for how to accurately write common units and quantums can be found at: http://www.wjgnet.com/2150-5330/g_info_20100107160355.htm.

Abbreviations

Standard abbreviations should be defined in the abstract and on first mention in the text. In general, terms should not be abbreviated unless they are used repeatedly and the abbreviation is helpful to the reader. Permissible abbreviations are listed in Units, Symbols and Abbreviations: A Guide for Biological and Medical Editors and Authors (Ed. Baron DN, 1988) published by The Royal Society of Medicine, London. Certain commonly used abbreviations, such as DNA, RNA, HIV, LD50, PCR, HBV, ECG, WBC, RBC, CT, ESR, CSF, IgG, ELISA, PBS, ATP, EDTA, mAb, can be used directly without further explanation.

Italics

Quantities: *t* time or temperature, *c* concentration, *A* area, *l* length, *m* mass, *V* volume.

Genotypes: *gyrA*, *arg 1*, *c myc*, *c fos*, *etc.*

Restriction enzymes: *EcoRI*, *HindIII*, *BamHI*, *Kbo I*, *Kpn I*, *etc.*

Biology: *H. pylori*, *E. coli*, *etc.*

Examples for paper writing

Editorial: http://www.wjgnet.com/2150-5330/g_info_20100316080010.htm

Frontier: http://www.wjgnet.com/2150-5330/g_info_20100316102300.htm

Topic highlight: http://www.wjgnet.com/2150-5330/g_info_20100316080012.htm

Observation: http://www.wjgnet.com/2150-5330/g_info_20100316080004.htm

Guidelines for basic research: http://www.wjgnet.com/2150-5330/g_info_20100316103422.htm

Guidelines for clinical practice: http://www.wjgnet.com/2150-5330/g_info_20100316103458.htm

Review: http://www.wjgnet.com/2150-5330/g_info_20100316080006.htm

Original articles: http://www.wjgnet.com/2150-5330/g_info_20100316080000.htm

Brief articles: http://www.wjgnet.com/2150-5330/g_info_20100316105425.htm

Case report: http://www.wjgnet.com/2150-5330/g_info_20100107153410.htm

Letters to the editor: <http://www.wjgnet.com/2150-5330/>

[g_info_20100107154228.htm](http://www.wjgnet.com/2150-5330/g_info_20100107154228.htm)

Book reviews: http://www.wjgnet.com/2150-5330/g_info_20100316105850.htm

Guidelines: http://www.wjgnet.com/2150-5330/g_info_20100316105919.htm

SUBMISSION OF THE REVISED MANUSCRIPTS AFTER ACCEPTED

Authors must revise their manuscript carefully according to the revision policies of Baishideng Publishing Group Co., Limited. The revised version, along with the signed copyright transfer agreement, responses to the reviewers, and English language Grade B certificate (for non-native speakers of English), should be submitted to the online system *via* the link contained in the e-mail sent by the editor. If you have any questions about the revision, please send e-mail to esps@wjgnet.com.

Language evaluation

The language of a manuscript will be graded before it is sent for revision. (1) Grade A: priority publishing; (2) Grade B: minor language polishing; (3) Grade C: a great deal of language polishing needed; and (4) Grade D: rejected. Revised articles should reach Grade A or B.

Copyright assignment form

Please download a Copyright assignment form from http://www.wjgnet.com/2150-5330/g_info_20100107155448.htm.

Responses to reviewers

Please revise your article according to the comments/suggestions provided by the reviewers. The format for responses to the reviewers' comments can be found at: http://www.wjgnet.com/2150-5330/g_info_20100107154656.htm.

Proof of financial support

For paper supported by a foundation, authors should provide a copy of the document and serial number of the foundation.

Links to documents related to the manuscript

WJGP will be initiating a platform to promote dynamic interactions between the editors, peer reviewers, readers and authors. After a manuscript is published online, links to the PDF version of the submitted manuscript, the peer-reviewers' report and the revised manuscript will be put on-line. Readers can make comments on the peer reviewer's report, authors' responses to peer reviewers, and the revised manuscript. We hope that authors will benefit from this feedback and be able to revise the manuscript accordingly in a timely manner.

Science news releases

Authors of accepted manuscripts are suggested to write a science news item to promote their articles. The news will be released rapidly at EurekAlert/AAAS (<http://www.eurekalert.org>). The title for news items should be less than 90 characters; the summary should be less than 75 words; and main body less than 500 words. Science news items should be lawful, ethical, and strictly based on your original content with an attractive title and interesting pictures.

Publication fee

WJGP is an international, peer-reviewed, OA, online journal. Articles published by this journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. Authors of accepted articles must pay a publication fee. Publication fee: 600 USD per article. Editorial, topic highlights, book reviews and letters to the editor are published free of charge.